Advances in sequencing technologies and bioinformatics have now made it possible to study comprehensively the complex landscape of the cancer genome as never before. Novel targets are being identified and conventional methods of categorizing cancer subtypes merely based on the microscopic findings are giving way to molecular genotyping. Investigators engaged in patient oriented cancer research today need to be adept in translating the rapidly emerging data from genomic analyses to the clinic. Furthermore, clinical investigators should be adequately trained to assess the comparative effectiveness of various modalities used for diagnosis and therapy to optimize clinical practice and contain the soaring health care costs. We are applying for the Paul Calabresi Career Development Award for Clinical Oncology to achieve these goals by training the next generation of clinician-investigators well versed in the three key areas relevant to patient oriented cancer research today: Cancer Genomics, Translational Medicine/Clinical Trials and Comparative Effectiveness Research. We propose to use the exceptional resources at Washington University (WU) including The Genomics Institute, Siteman Cancer Center, Clinical Research Training Center and Institute for Public Health to train the individuals selected for this program. The broad goal of the WU Clinical Oncology (K12) Paul Calabresi Career Development Program is to train a new generation of highly skilled investigators with specialized expertise who will be well prepared to lead cancer research during this exciting period with the emerging body of information from cancer genomics. Within these priorities we will focus our training in three key areas, 1) Cancer genomics, bioinformatics, analysis and their application in patient oriented research, 2) Translational Medicine with special emphasis on translating rapidly emerging genomic data to the clinic, clinical trial design, execution and analysis in this era of personalized therapy and 3 Comparative Effectiveness Research. To facilitate this, PC scholars will choose one of the three elective tracks offered by the WU PC CDP: Cancer Genomics track, Translational Medicine/ Clinical Trialist track and CER track. We propose to develop and lead collaborative learning networks with the CTSAs and other career development programs at WU to share best practices and knowledge and disseminate new training programs and curricula beyond WU Clinical Oncology K12 Program to broaden the impact of this program. WU PC scholars and other investigators benefitting from this program will learn to perform research that will provide new information addressing current evidence gaps and how to translate this knowledge into improvements in the outcomes of patients with cancer.

Public Health Relevance

We are able to detect changes in the genes inside a cell more accurately now than ever before. Newer drugs that effectively block the function of certain genes can be quite effective in some patients with cancer. The costs of cancer care are increasing. To tackle all these issues effectively, the newer generation of investigators will need to be trained in all these areas as is being proposed in this application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
1K12CA167540-01
Application #
8289787
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
2012-04-16
Project End
2017-03-31
Budget Start
2012-04-16
Budget End
2013-03-31
Support Year
1
Fiscal Year
2012
Total Cost
$107,272
Indirect Cost
$7,279
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Okeyo-Owuor, T; White, B S; Chatrikhi, R et al. (2015) U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing. Leukemia 29:909-17
Wang, Tzu-Fei; Ahluwalia, Rohan; Fiala, Mark A et al. (2014) The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. Leuk Lymphoma 55:337-41
Patel, Aalok P; Crabtree, Traves D; Bell, Jennifer M et al. (2014) National patterns of care and outcomes after combined modality therapy for stage IIIA non-small-cell lung cancer. J Thorac Oncol 9:612-21
Touma, Waseem; Koro, Sami S; Ley, Jessica et al. (2014) Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck. Oral Oncol 50:895-900
Carpenter, Christopher R; Avidan, Michael S; Wildes, Tanya et al. (2014) Predicting geriatric falls following an episode of emergency department care: a systematic review. Acad Emerg Med 21:1069-82
Miller, Christopher A; White, Brian S; Dees, Nathan D et al. (2014) SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol 10:e1003665
Spencer, Christopher R; Gay, Hiram A; Haughey, Bruce H et al. (2014) Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life. Cancer 120:3994-4002
Wildes, Tanya M; Rosko, Ashley; Tuchman, Sascha A (2014) Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol 32:2531-40
Wildes, Tanya M; Stirewalt, Derek L; Medeiros, Bruno et al. (2014) Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic. J Natl Compr Canc Netw 12:128-36
Waqar, Saiama N; Robinson, Clifford; Bradley, Jeffrey et al. (2014) A phase I study of temsirolimus and thoracic radiation in non--small-cell lung cancer. Clin Lung Cancer 15:119-23

Showing the most recent 10 out of 14 publications